Journal Article

Pathogenesis, diagnosis and treatment of Rasmussen encephalitis

C. G. Bien, T. Granata, C. Antozzi, J. H. Cross, O. Dulac, M. Kurthen, H. Lassmann, R. Mantegazza, J.-G. Villemure, R. Spreafico and C. E. Elger

in Brain

Published on behalf of The Guarantors of Brain

Volume 128, issue 3, pages 454-471
Published in print March 2005 | ISSN: 0006-8950
Published online February 2005 | e-ISSN: 1460-2156 | DOI:
Pathogenesis, diagnosis and treatment of Rasmussen encephalitis

Show Summary Details


Rasmussen encephalitis (RE) is a rare but severe immune-mediated brain disorder leading to unilateral hemispheric atrophy, associated progressive neurological dysfunction and intractable seizures. Recent data on the pathogenesis of the disease, its clinical and paraclinical presentation, and therapeutic approaches are summarized. Based on these data, we propose formal diagnostic criteria and a therapeutic pathway for the management of RE patients.

Keywords: encephalitis; epilepsy; pathophysiology; diagnostic criteria; therapy; AED = anti-epilepsy drug; BBB = blood–brain barrier; CTL = cytotoxic T lymphocyte; EPC = epilepsia partialis continua; FDG = fluorodeoxyglucose; GluR3 = glutamate receptor subunit 3; GrB = Granzyme B; HE = hemispherectomy or any of its variants; IVIG = intravenous immunoglobulins; PEX/PAI = plasma exchange/protein A IgG immuno-adsorption; RE = Rasmussen encephalitis; SPECT = single photon emission computed tomography; TCR = T cell receptors

Journal Article.  15129 words.  Illustrated.

Subjects: Neurology ; Neuroscience

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.